8月 2026Novaliq的市場佔有率分析

novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on eyesol®, the first and only water-free technology worldwide for ophthalmology products.

行業: N/A

域名novaliq.com

成立年份2004

僱員51 - 200

年度營收$10M - $15M

Novaliq

Novaliq（包含公司地區）

novaliq.com

查看更多網站流量與參與度資訊

Novaliq截至 8月 2026 的總收入為 10M - 15M

Novaliq 熱門網域產生的總收入

Novaliq 熱門網域 3 年內的總收入

Novaliq 熱門網域的總收入

novaliq.com10M - 15M

透過銷售情報查看更多內容

Novaliq的熱門網域總造訪量

了解Novaliq市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

novaliq.com5.6K

透過銷售情報查看更多內容

Novaliq的熱門網域平均造訪時長

分析Novaliq參與度指標。

過去 3 個月平均造訪時長

子公司細目

novaliq.com00:00:10

透過銷售情報查看更多內容

Novaliq的熱門網域平均頁面瀏覽量

了解Novaliq如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

novaliq.com1.62

透過銷售情報查看更多內容

Novaliq按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

使用的熱門技術Novaliq

这些是Novaliq顶级域名使用的行业网站技术

小工具 (7)

reCAPTCHA

轉換與分析 (3)

Google Analytics

行動裝置 (3)

Meta Viewport

內容管理系統 (2)

WordPress

更多技術

8

檢視所有

新聞與訊號來自Novaliq

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Hengrui partnered with Novaliq GmbH on Jul 1st '19.Hengrui Pharma, a globally active pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH ("Novaliq"), a biopharmaceutical company focused on first-in-class and best-in-class ophthalmic therapies based on its unique water-free EyeSol platform technology, today announced that on June 23, 2026, the Chinese National Medical Products Administration (NMPA) approved Heng Yi (0.1% cyclosporine eye drops) for the treatment of patients with dry eye disease, aiming to increase tear secretion in patients with reduced tear production and alleviate disease symptoms.

新聞Sonja Kroesser at Novaliq GmbH recognized as Top 25 Women Leaders in Biotechnology of 2022 on Nov 17th '22.Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol ® water-free technology, is proud to announce that today its own Sonja Kroesser, Vice President and Head of Preclinical and Clinical Development, was named as a Top 25 Women Leaders in Biotechnology of 2022 by the Healthcare Technology Report.

新聞Sonja Kroesser at Novaliq GmbH recognized as Top 25 Women Leaders in Biotechnology of 2022 on Jan 17th '19.Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol ® water-free technology, is proud to announce that today its own Sonja Kroesser, Vice President and Head of Preclinical and Clinical Development, was named as a Top 25 Women Leaders in Biotechnology of 2022 by the Healthcare Technology Report.